399 related articles for article (PubMed ID: 22261031)
1. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients.
Clark RA; Watanabe R; Teague JE; Schlapbach C; Tawa MC; Adams N; Dorosario AA; Chaney KS; Cutler CS; Leboeuf NR; Carter JB; Fisher DC; Kupper TS
Sci Transl Med; 2012 Jan; 4(117):117ra7. PubMed ID: 22261031
[TBL] [Abstract][Full Text] [Related]
2. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.
Querfeld C; Mehta N; Rosen ST; Guitart J; Rademaker A; Gerami P; Kuzel TM
Leuk Lymphoma; 2009 Dec; 50(12):1969-76. PubMed ID: 19860617
[TBL] [Abstract][Full Text] [Related]
3. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors.
Campbell JJ; Clark RA; Watanabe R; Kupper TS
Blood; 2010 Aug; 116(5):767-71. PubMed ID: 20484084
[TBL] [Abstract][Full Text] [Related]
4. Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells.
Watanabe R; Gehad A; Yang C; Scott LL; Teague JE; Schlapbach C; Elco CP; Huang V; Matos TR; Kupper TS; Clark RA
Sci Transl Med; 2015 Mar; 7(279):279ra39. PubMed ID: 25787765
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia.
Mohan SR; Clemente MJ; Afable M; Cazzolli HN; Bejanyan N; Wlodarski MW; Lichtin AE; Maciejewski JP
Haematologica; 2009 Oct; 94(10):1407-14. PubMed ID: 19794084
[TBL] [Abstract][Full Text] [Related]
6. Single-Cell RNA Sequencing Reveals Tissue Compartment-Specific Plasticity of Mycosis Fungoides Tumor Cells.
Rindler K; Bauer WM; Jonak C; Wielscher M; Shaw LE; Rojahn TB; Thaler FM; Porkert S; Simonitsch-Klupp I; Weninger W; Mayerhoefer ME; Farlik M; Brunner PM
Front Immunol; 2021; 12():666935. PubMed ID: 33968070
[TBL] [Abstract][Full Text] [Related]
7. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
Jiang L; Yuan CM; Hubacheck J; Janik JE; Wilson W; Morris JC; Jasper GA; Stetler-Stevenson M
Br J Haematol; 2009 Apr; 145(2):173-9. PubMed ID: 19236377
[TBL] [Abstract][Full Text] [Related]
8. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?
Ni X; Hazarika P; Zhang C; Talpur R; Duvic M
Clin Cancer Res; 2001 Sep; 7(9):2682-92. PubMed ID: 11555580
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab in T-cell malignancies.
Dearden CE; Matutes E; Catovsky D
Med Oncol; 2002; 19 Suppl():S27-32. PubMed ID: 12180489
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas.
de Masson A; Guitera P; Brice P; Moulonguet I; Mouly F; Bouaziz JD; Battistella M; Madelaine I; Roux J; Ram-Wolff C; Cayuela JM; Bachelez H; Bensussan A; Michel L; Bagot M
Br J Dermatol; 2014 Mar; 170(3):720-4. PubMed ID: 24438061
[TBL] [Abstract][Full Text] [Related]
11. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
12. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
[TBL] [Abstract][Full Text] [Related]
13. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
Osuji N; Del Giudice I; Matutes E; Morilla A; Owusu-Ankomah K; Morilla R; Dunlop A; Catovksy D
Leuk Lymphoma; 2005 May; 46(5):723-7. PubMed ID: 16019510
[TBL] [Abstract][Full Text] [Related]
14. Immunopathogenesis of mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma).
Wong HK
G Ital Dermatol Venereol; 2008 Dec; 143(6):375-83. PubMed ID: 19169210
[TBL] [Abstract][Full Text] [Related]
15. Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma/mycosis fungoides.
Chong BF; Wilson AJ; Gibson HM; Hafner MS; Luo Y; Hedgcock CJ; Wong HK
Clin Cancer Res; 2008 Feb; 14(3):646-53. PubMed ID: 18245523
[TBL] [Abstract][Full Text] [Related]
16. CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment.
Hotta R; Ohira M; Matsuura T; Muraoka I; Tryphonopoulos P; Fan J; Tekin A; Selvaggi G; Levi D; Ruiz P; Ricordi C; Vianna R; Ohdan H; Waldmann H; Tzakis AG; Nishida S
PLoS One; 2016; 11(8):e0161618. PubMed ID: 27560943
[TBL] [Abstract][Full Text] [Related]
17. Immunity 12 years after alemtuzumab in RA: CD5⁺ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses.
Anderson AE; Lorenzi AR; Pratt A; Wooldridge T; Diboll J; Hilkens CM; Isaacs JD
Rheumatology (Oxford); 2012 Aug; 51(8):1397-406. PubMed ID: 22447884
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
Hu Y; Turner MJ; Shields J; Gale MS; Hutto E; Roberts BL; Siders WM; Kaplan JM
Immunology; 2009 Oct; 128(2):260-70. PubMed ID: 19740383
[TBL] [Abstract][Full Text] [Related]
19. Enhanced expression of T-cell activation and natural killer cell antigens indicates systemic anti-tumor response in early primary cutaneous T-cell lymphoma.
Asadullah K; Friedrich M; Döcke WD; Jahn S; Volk HD; Sterry W
J Invest Dermatol; 1997 May; 108(5):743-7. PubMed ID: 9129226
[TBL] [Abstract][Full Text] [Related]
20. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation.
Ratzinger G; Reagan JL; Heller G; Busam KJ; Young JW
Blood; 2003 Feb; 101(4):1422-9. PubMed ID: 12393688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
